The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000470392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/03/2026
Date registered
Help: Date registered
16/04/2026
Date last updated
Help: Date last updated
2/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Ultra-hyPofractionated stereotactic Radiation therapy for de nOvo Metastatic ProsTate cancer (PROMPT)
Scientific title
Assessing toxicity and quality of life in patients treated with prostate stereotactic ablative radiation therapy for de novo metastatic prostate cancer.
Additional trial identifiers [1] 316884 0
None
Universal Trial Number (UTN)
Trial acronym
PROMPT
Related trial records

Health condition
Health condition(s) studied:
De novo metastatic prostate cancer 341279 0
Condition category
Condition code
Cancer 337350 337350 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Patients will receive stereotactic ablative body radiotherapy (SABR) to the prostate delivered in five fractions, one fraction per week. Each SABR session will take approximately 30 minutes, This study will aim to deliver 5-fraction prostate SABR 35 GY in 5 fractions to the prostate.

SABR will be prescribed by treating radiation oncologist. Adherence to the intervention will be assessed by review of medical records.
All participants will be on standard care systemic therapy which is an eligibility criteria for the trial, which typically includes androgen deprivation therapy +/- androgen receptor pathway inhibitor. The systemic therapy agent, dose, frequency and administration is dependent on that prescribed by the clinician. The timing of standard care systemic therapy relative to SABR delivery, i.e before or after radiotherapy, will be determined by treating clinicians and independent of patient’s enrolment in the current trial.
Intervention code [1] 333579 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344868 0
Acute (<3 months) effects on urinary, bowel and sexual quality of life. This will be assessed as a composite outcome.
Timepoint [1] 344868 0
4 weeks and 3 months post completion of SABR treatment (cumulative)
Secondary outcome [1] 459570 0
Late (>6 months to 5 years) effects on urinary quality of life
Timepoint [1] 459570 0
At 6, 12, 18, 24, 36, 48 and 60 months post- completion SABR treatment (cumulative)
Secondary outcome [2] 459571 0
Acute (<3 months) GU function clinician-reported toxicity
Timepoint [2] 459571 0
End of treatment, and 4 weeks and 3 months post-completion of SABR treatment (cumulative)
Secondary outcome [3] 459572 0
Late (>6 months to 5 years) clinician reported GU toxicity
Timepoint [3] 459572 0
At 6, 12, 18, 24, 36, 48 and 60 months post- completion SABR treatment (cumulative)
Secondary outcome [4] 459573 0
Time to castrate resistant disease
Timepoint [4] 459573 0
Determined during follow-up at 3, 6, 12, 18, 24, 36, 48, and 60 months post-completion of SABR treatment
Secondary outcome [5] 459574 0
To determine failure free survival
Timepoint [5] 459574 0
Determined during follow-up at 3, 6, 12, 18, 24, 36, 48, and 60 months post-completion of SABR treatment
Secondary outcome [6] 459575 0
Overall survival
Timepoint [6] 459575 0
Determined during follow-up at 3, 6, 12, 18, 24, 36, 48, and 60 months post-completion of SABR treatment
Secondary outcome [7] 460057 0
Late (>6 months to 5 years) effects on bowel quality of life
Timepoint [7] 460057 0
At 6, 9, 12, 18, 24, 36, 48 and 60 months post- completion SABR treatment (cumulative)
Secondary outcome [8] 460058 0
Late (>6 months to 5 years) effects on sexual function quality of life
Timepoint [8] 460058 0
At 6, 9, 12, 18, 24, 36, 48 and 60 months post- completion SABR treatment (cumulative)
Secondary outcome [9] 460062 0
Acute (<3 months) GI function clinician-reported toxicity
Timepoint [9] 460062 0
End of treatment, and 4 weeks and 3 months post-completion of SABR treatment (cumulative)
Secondary outcome [10] 460063 0
Acute (<3 months) sexual function clinician-reported toxicity
Timepoint [10] 460063 0
End of treatment, and 4 weeks and 3 months post-completion of SABR treatment (cumulative)
Secondary outcome [11] 460065 0
Late (>6 months to 5 years) clinician reported GI function toxicity
Timepoint [11] 460065 0
At 6, 12, 18, 24, 36, 48 and 60 months post- completion SABR treatment (cumulative)
Secondary outcome [12] 460066 0
Late (>6 months to 5 years) clinician reported sexual function toxicity
Timepoint [12] 460066 0
At 6, 12, 18, 24, 36, 48 and 60 months post- completion SABR treatment (cumulative)

Eligibility
Key inclusion criteria
- Histologically confirmed prostate adenocarcinoma.
- Evidence of metastatic disease (M1a/b/c) on prostate specific membrane antigen positron emission tomography (PSMA PET) or CT/ bone scan staging
- Metastatic prostate cancer at initial diagnosis (de novo)
- Age 18 or over
- ECOG 0-2
- Fit for (and commenced/ planned for) optimal systemic therapy including continuous androgen deprivation therapy +/- androgen receptor pathway inhibitors +/- chemotherapy
- Capacity to consent to treatment and comply with radiation therapy treatment, follow-up schedule and completion of QOL questionnaires

Minimum age
18 Years
Maximum age
No limit
Sex
Males
Healthy volunteers
No
Key exclusion criteria
- Prior definitive prostate cancer treatment (prostatectomy and/ or prostate radiotherapy)
- Prior pelvic radiotherapy
- Contraindication for magnetic resonance imaging

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321478 0
Hospital
Name [1] 321478 0
Alfred Hospital
Country [1] 321478 0
Australia
Primary sponsor type
Hospital
Name
Alfred Hospital
Address
Country
Australia
Secondary sponsor category [1] 324228 0
None
Name [1] 324228 0
Address [1] 324228 0
Country [1] 324228 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320011 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320011 0
Ethics committee country [1] 320011 0
Australia
Date submitted for ethics approval [1] 320011 0
04/02/2026
Approval date [1] 320011 0
17/04/2026
Ethics approval number [1] 320011 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149142 0
Prof Wee Loon Ong
Address 149142 0
Alfred Hospital, 55 Commercial Road, Melbourne 3002, VIC
Country 149142 0
Australia
Phone 149142 0
+61 3 90762360
Fax 149142 0
Email 149142 0
Contact person for public queries
Name 149143 0
Wee Loon Ong
Address 149143 0
Alfred Hospital, 55 Commercial Road, Melbourne 3002, VIC
Country 149143 0
Australia
Phone 149143 0
+61 3 90762360
Fax 149143 0
Email 149143 0
Contact person for scientific queries
Name 149144 0
Wee Loon Ong
Address 149144 0
Alfred Hospital, 55 Commercial Road, Melbourne 3002, VIC
Country 149144 0
Australia
Phone 149144 0
+61 3 90762360
Fax 149144 0
Email 149144 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.